Nimacimab Biosimilar - Research Grade

Human

CNR1ï؟½

5mg/ml

IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P21554

Blue ice

The cannabinoid receptor CNR1 (CB1) is a G-protein-coupled receptor with broad roles in metabolic and neurological signaling. This research-grade human IgG4 kappa antibody is an unconjugated, non-therapeutic analog of nimacimab, expressed in CHO cells against human CNR1. For research use only, it is prepared in a low-endotoxin format appropriate for in vivo studies and supplied in scalable milligram (mg) to gram (g) quantities to support bulk and high-throughput work. It functions as a dependable reagent for receptor characterization, functional assays, ligand-competition studies, and preclinical models examining cannabinoid-receptor biology. Its reproducible quality supports demanding workflows that consume reagent at scale.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks